The International Advisory Committee on Clinical Trials in MS is seeking nominations for new members to join the committee for the term commencing in January 2023.
The deadline for nominations is 30 September 2022. Download the Call for Nomination information here.
To be considered for membership, individuals must hold expertise in MS clinical research or in aspects of MS clinical trials including, but not limited to, trials design and execution, imaging, and biostatistics. Other areas of interest include rehabilitation, epidemiology, other demyelinating diseases such as NMO- SD or MOGAD, paediatric MS as well as implementation science. Individuals may nominate themselves.
Committee membership terms are generally for two years with the possibility of reappointment for additional two-year terms up to a maximum of three consecutive terms. Approximately half of the members of the committee are from North America and half from Europe, reflecting the jurisdictions of the sponsoring organisations. At their discretion, the Sponsors may jointly appoint certain members representing additional geographies.
The committee is committed to ensuring balance through equal gender representation and to creating a diverse and inclusive culture where all individuals feel welcome and desire to engage with the committee.
Members of the Committee are asked to attend administrative and planning meetings of the Committee, which are held at least annually at the ECTRIMS congresses, and additional virtual meetings throughout the year. Committee members also participate in workshops and consensus conferences held to pursue specific topics relevant to clinical trials-related projects in MS.
Individuals interested in nominating themselves or colleagues may do so by completing an online nomination form available here. A subcommittee of the International Advisory Committee on Clinical Trials in MS will consider nominations and make recommendations on new members to the Sponsors.
About the International Advisory Committee on Clinical Trials in MS
The Committee was formed and supported by the US National Multiple Sclerosis Society (NMSS) over 30 years ago, and since 2009 it has been sponsored and supported jointly by the Society and the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).
The mission of the International Advisory Committee on Clinical Trials in Multiple Sclerosis is to provide perspective and guidance to the multiple sclerosis (MS) scientific and clinical community related to planning and implementation of clinical trials of MS therapies and allied topics.
The Committee conceives of and prioritises timely clinical trials-related projects to be undertaken as a whole, in task forces, panel groups, or as larger Committee-sponsored activities. Projects may be pursued in consensus-building international conferences and workshops and through other mechanisms as needed. Outcomes of projects are prepared for publication in high-impact relevant scientific journals for wider distribution to the MS community.
(Recent projects and links to publications can be found here)
A list of current members of the committee can be found here. Questions may be directed to:
National MS Society email@example.com